Shorter Radiation Course for Cervical Cancer
Official title: Hypofractionated Radiotherapy in Cervical Cancer: A Non-inferiority Randomized Controlled Trial
Run by All India Institute of Medical Sciences · NCT07625943 · Data updated 2026-11-12
This study tests whether a condensed, hypofractionated radiation plan with chemotherapy works as well as the standard longer course for women with locally advanced cervical cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | Women only |
| Enrollment | 396 (estimated) |
| Sponsor | All India Institute of Medical Sciences Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (New Delhi, New Delhi) |
| Status | Recruiting |
| Started | January 15, 2026 |
| Main results expected | July 15, 2029 |
| Study ends | January 30, 2030 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT07625943 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18–65 with locally advanced cervical cancer (FIGO IB3–IIIC1) suitable for definitive concurrent chemoradiation and with adequate organ function.
✕Probably not a fit
Patients with more advanced disease (e.g., IIIC2/IVA/IVB), poor performance status, or conditions compromising radiotherapy tolerance may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, parallel-group randomized trial comparing hypofractionated external beam radiotherapy plus the same chemotherapy and brachytherapy to the standard fractionated schedule. The goal is to determine non-inferiority in pelvic loco-regional control while potentially improving feasibility and adherence in high-burden settings. Eligible participants are women 18–65 with histologically confirmed cervical cancer (FIGO IB3–IIIC1) suitable for definitive concurrent chemoradiation. The study is conducted in India through a collaboration between AIIMS, Varian, and Siemens Healthineers, enrolling patients treated with cisplatin-based chemoradiation and image-guided brachytherapy. Primary outcomes focus on disease control within the pelvis and treatment delivery metrics.
Why it matters
Potential benefit: If successful, the shorter radiation course could reduce treatment time and patient burden while preserving effectiveness.
How similar studies have gone: Non-inferiority approaches with hypofractionation have shown promise in other settings, but this specific regimen in locally advanced cervical cancer is under evaluation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Female participants aged 18 to 65 years. Histopathologically confirmed cervical cancer. FIGO stage IB3 to IIIC1. Suitable for definitive concurrent chemoradiation. ECOG performance status 0 to 2. Adequate hematological, renal, and hepatic function. Able and willing to provide informed consent. Exclusion Criteria: ECOG performance status 3 or higher. FIGO stage IIIC2, IVA, or IVB. Prior pelvic radiotherapy or prior chemotherapy for cervical cancer. Inflammatory bowel disease. Hydronephrosis. Pregnancy. Synchronous malignancy. Any serious medical condition that would interfere with protocol treatment or follow-up.
Where it's running
-
National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India
New Delhi, New Delhi, India Recruiting
Study contacts
- Study coordinator: Karun Kamboj, MD - Radiation Oncology
- Email: karunkamboj04@aiims.edu
- Phone: 9416613389
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.